text: Yo, check it out, let me break it down for ya,
  Cryopreserved peripheral blood stem cell, PBSC, yeah,
  Infusion-related reactions, they can get real rough,
  Cardiac, neurologic, complications, that's tough.
  
  Preliminary analysis, they had a hunch,
  Limiting the nucleated cell dose, they wanted to crunch,
  December 2007, a policy came through,
  Dose less than 1.63 times ten to the ninth, that's true.
  
  They wanted to see the impact, what would it do,
  On safety, schedules, engraftment, costs too,
  Two years before, and two years after, they compared,
  Autologous stem cell transplants, they dared.
  
  325 ASCTs, 288 patients in the mix,
  Then 519 ASCTs, 479 patients, that's the fix,
  Multi-day infusions, they started to rise,
  From 6% to 24%, a big surprise.
  
  But hold up, the adverse events took a dive,
  From 4% to 0.6%, that's how they strive,
  Grade 3-5 severe infusion-related, SAEs,
  Decreased significantly, yo, that's the blaze.
  
  No delay in engraftment, no extra dough,
  Multiday infusions, they didn't slow,
  The conclusion is clear, the TNC dose was key,
  Improved safety without compromise, can't you see?
  
  So remember, my people, when it comes to this game,
  Limiting the daily dose, it's not a shame,
  Autologous stem cell transplants, they can be grand,
  With the right precautions, we can make a stand.